Pacific Biosciences shares fall 15% after first-quarter revenue misses estimates
Updated
Updated · MarketWatch · May 8
Pacific Biosciences shares fall 15% after first-quarter revenue misses estimates
3 articles · Updated · MarketWatch · May 8
The stock dropped to $1.41 after revenue came in at $37.2 million, below analysts' $39.9 million forecast, while adjusted loss matched estimates at 12 cents a share.
Chief executive Christian Henry said weaker-than-expected Vega system shipments reflected soft US demand as academic funding stayed under pressure, while Asia-Pacific revenue fell 16% year on year.
Chinese service providers are awaiting the SPRQ-Nx launch, and the company kept 2026 revenue guidance at $165 million to $175 million, around the $171.5 million analyst consensus.
With its stock falling, can PacBio's new cost-cutting sequencing tech spark a major turnaround?
PacBio is powering a massive AI project. How will this move beyond genomics reshape the future of medicine?